CN Patent

CN101918373B — 作为akt蛋白激酶抑制剂的嘧啶基环戊烷

Assigned to Genentech Inc · Expires 2013-06-05 · 13y expired

What this patent protects

本发明提供式I的化合物，包括它的互变异构体、拆分的对映异构体、非对映异构体、溶剂合物、代谢产物、盐和可药用前药。还提供使用本发明的化合物作为AKT蛋白激酶抑制剂的方法以及本发明的化合物用于治疗过度增殖性疾病例如癌症的方法。

USPTO Abstract

本发明提供式I的化合物，包括它的互变异构体、拆分的对映异构体、非对映异构体、溶剂合物、代谢产物、盐和可药用前药。还提供使用本发明的化合物作为AKT蛋白激酶抑制剂的方法以及本发明的化合物用于治疗过度增殖性疾病例如癌症的方法。

Drugs covered by this patent

selumetinib-sulfate (SELUMETINIB SULFATE)

Patent Metadata

Patent number: CN101918373B
Jurisdiction: CN
Classification: —
Expires: 2013-06-05
Drug substance claim: No
Drug product claim: No
Assignee: Genentech Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.